OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
11961060

Interojo Co Ltd

Medical Equipment, Supplies & DistributionVerified

Interojo Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.35, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.6, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk in the short term. In terms of profitability, Interojo Co Ltd demonstrates a return on equity (ROE) of 8.24% and a return on assets (ROA) of 5.28%. These figures are in line with the industry's preferred metrics, which emphasize efficient use of equity and asset base to generate returns. The company's operating income of 18,389,291,610 KRW and net income of 12,937,842,300 KRW reflect a strong performance in converting revenue into profit. The company's revenue is primarily concentrated in the domestic market, with a significant portion of its sales coming from Korea. While Interojo Co Ltd has expanded into overseas markets, the exact distribution of revenue across regions is not disclosed. This concentration could expose the company to regional economic fluctuations and regulatory changes. Interojo Co Ltd's growth trajectory is supported by its operating cash flow of 25,339,040,300 KRW and free cash flow of 12,216,170,160 KRW, indicating the company's ability to generate cash from operations and fund future growth. The company's capital expenditure of -6,925,675,210 KRW suggests a reduction in investment in physical assets, which could be a strategic decision to focus on operational efficiency. The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The risk assessment highlights that net cash is negative after subtracting total debt, which could affect the company's ability to meet short-term obligations. However, the dilution risk is low, suggesting that the company is not likely to issue additional shares in the near term, which could dilute existing shareholders' equity. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's financial performance and risk profile remain stable, with no major disruptions reported in the latest filings or transcripts. The company's focus on maintaining a strong balance sheet and generating consistent cash flow supports its current financial position.

30-day price · 119610-230.00 (-1.2%)
Low$18400.00High$23100.00Close$19100.00As of14 May, 00:00 UTC
Profile
CompanyInterojo Co Ltd
Ticker119610.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Interojo Co Ltd is a Korea-based company engaged in the manufacture and marketing of contact lenses, including silicone hydrogel lenses, sodium hyaluronate lenses, and multifocal vision lenses, distributing its products in domestic and overseas markets.

Classification. Interojo Co Ltd is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a classification confidence of 0.92.

Interojo Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.35, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.6, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk in the short term. In terms of profitability, Interojo Co Ltd demonstrates a return on equity (ROE) of 8.24% and a return on assets (ROA) of 5.28%. These figures are in line with the industry's preferred metrics, which emphasize efficient use of equity and asset base to generate returns. The company's operating income of 18,389,291,610 KRW and net income of 12,937,842,300 KRW reflect a strong performance in converting revenue into profit. The company's revenue is primarily concentrated in the domestic market, with a significant portion of its sales coming from Korea. While Interojo Co Ltd has expanded into overseas markets, the exact distribution of revenue across regions is not disclosed. This concentration could expose the company to regional economic fluctuations and regulatory changes. Interojo Co Ltd's growth trajectory is supported by its operating cash flow of 25,339,040,300 KRW and free cash flow of 12,216,170,160 KRW, indicating the company's ability to generate cash from operations and fund future growth. The company's capital expenditure of -6,925,675,210 KRW suggests a reduction in investment in physical assets, which could be a strategic decision to focus on operational efficiency. The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The risk assessment highlights that net cash is negative after subtracting total debt, which could affect the company's ability to meet short-term obligations. However, the dilution risk is low, suggesting that the company is not likely to issue additional shares in the near term, which could dilute existing shareholders' equity. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's financial performance and risk profile remain stable, with no major disruptions reported in the latest filings or transcripts. The company's focus on maintaining a strong balance sheet and generating consistent cash flow supports its current financial position.
Key takeaways
  • Interojo Co Ltd has a conservative capital structure with a debt-to-equity ratio of 0.35, indicating a relatively low reliance on debt financing.
  • The company's liquidity position is strong, with a current ratio of 2.6, but its net cash position is negative after subtracting total debt.
  • Interojo Co Ltd demonstrates a return on equity (ROE) of 8.24% and a return on assets (ROA) of 5.28%, which are in line with industry standards.
  • The company's revenue is primarily concentrated in the domestic market, which could expose it to regional economic fluctuations.
  • Interojo Co Ltd's growth trajectory is supported by its operating cash flow of 25,339,040,300 KRW and free cash flow of 12,216,170,160 KRW.
  • The company faces a medium liquidity risk and a low dilution risk, with no major disruptions reported in recent filings or transcripts.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$118.44B
Gross profit$41.96B
Operating income$18.39B
Net income$12.94B
R&D
SG&A
D&A
SBC
Operating cash flow$25.34B
CapEx-$6.93B
Free cash flow$12.22B
Total assets$244.89B
Total liabilities$87.85B
Total equity$157.04B
Cash & equivalents$15.34B
Long-term debt$55.64B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$118.44B$18.39B$12.94B$12.22B
FY-1$115.84B$4.48B$184.3M-$438.8M
FY-2$119.30B$5.19B$3.16B-$3.01B
FY-3$117.82B$24.17B$18.64B$4.95B
FY-4$107.53B$22.64B$14.74B$9.21B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$244.89B$157.04B$15.34B
FY-1$234.40B$169.95B$19.28B
FY-2$269.50B$176.92B$5.84B
FY-3$259.31B$179.30B$2.06B
FY-4$230.49B$173.15B$10.62B
PeriodOCFCapExFCFSBC
FY0$25.34B-$6.93B$12.22B
FY-1$19.78B-$3.31B-$438.8M
FY-2$8.49B-$8.27B-$3.01B
FY-3$12.05B-$17.31B$4.95B
FY-4$14.33B-$10.79B$9.21B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$31.62B$6.24B$4.21B$4.80B
FQ-1$32.35B$3.63B$3.85B$3.72B
FQ-2$31.34B$6.34B$3.47B$4.84B
FQ-3$23.13B$2.18B$1.41B$2.61B
FQ-4$23.79B-$6.35B-$5.03B-$2.86B
FQ-5$33.10B$4.28B$3.79B$6.14B
FQ-6$26.64B$2.00B-$1.74B$241.8M
FQ-7$33.63B$5.53B$3.75B$4.33B
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$244.89B$157.04B$15.34B
FQ-1$220.25B$154.89B$6.53B
FQ-2$221.20B$156.16B$14.22B
FQ-3$235.07B$167.60B$27.03B
FQ-4$234.40B$169.95B$19.28B
FQ-5$251.53B$185.98B$14.56B
FQ-6$251.73B$182.38B$10.39B
FQ-7$277.00B$183.94B$13.63B
PeriodOCFCapExFCFSBC
FQ0$25.34B-$6.93B$4.80B
FQ-1$18.21B-$4.99B$3.72B
FQ-2$12.20B-$2.39B$4.84B
FQ-3$8.97B-$1.29B$2.61B
FQ-4$19.78B-$3.31B-$2.86B
FQ-5$11.62B-$2.94B$6.14B
FQ-6$11.43B-$2.55B$241.8M
FQ-7$5.99B-$1.97B$4.33B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$157.04B
Net cash-$40.31B
Current ratio2.6
Debt/Equity0.3
ROA5.3%
ROE8.2%
Cash conversion2.0%
CapEx/Revenue-5.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric119610Activity
Op margin15.5%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin10.9%8.6% medp25 2.7% · p75 12.7%above median
Gross margin35.4%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-5.9%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity35.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
Mean price target23,000.00 KRW
Median price target23,000.00 KRW
High price target23,000.00 KRW
Low price target23,000.00 KRW
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2,030.20 KRW
Last actual EPS1,007.00 KRW
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-14 00:32 UTC#0bf0cb72
Source: analysis-pipeline (hybrid)Generated: 2026-05-14 00:35 UTCJob: 62c1c4fb